tbuckley/cabot-search huggingface dataset:
Sacituzumab Govitecan in Patients With Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results From the Phase 2 TROPiCS-03 Basket Study
Authors: Loren Michel, Antonio Jimeno, Ammar Sukari, J. Thaddeus Beck, Joanne Chiu, Elizabeth Ahern, John Hilton, Caroline Even, Sylvie Zanetta, Sabeen Mekan, Jilpa Patel, Tia Wu, Ecaterina E. Dumbrava
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a programmed death-1 (PD-1) inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) is a Trop-2–directed antibody–drug conjugate approved for patients with certain previously treated solid tumors. Methods: TROPiCS-03 (NCT03964727) is an open-label, multicohort, phase 2 study evaluating SG in advanced solid tumors, including HNSCC. Adults with locally advanced or metastatic HNSCC that progressed following platinum-based chemotherapy and anti–PD-(ligand)1 therapy (given sequentially [either order] or in combination) were administered SG 10 mg/kg on days 1 and 8 of a 21-day cycle. The primary endpoint was investigator-assessed objective response rate (ORR). Secondary endpoints included duration of response (DoR), clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. Results: Patients (N=43) received a median of 3 (range, 2–9) prior anticancer regimens. ORR was 16% (95% confidence interval [CI], 7–31%), with 7 confirmed partial responses. CBR was 28% (95% CI, 15–44%). Median (95% CI) DoR, PFS, and OS were 4.2 (2.6–not reached), 4.1 (2.6–5.8), and 9.0 (7.1–10.5) months, respectively. The most common treatment-emergent adverse events (TEAEs) were diarrhea (47%), nausea (47%), and neutropenia (47%). Grade ≥3 TEAEs occurred in 58% of patients. Three patients died owing to TEAEs, with one event (septic shock) considered related to SG. Conclusions: These data demonstrate the clinical potential of Trop-2–directed therapy in managing heavily pretreated patients with advanced HNSCC.
Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study
Authors: Elisa Stein, Cornelia Heindrich, Kirsten Wittke, Claudia Kedor, Rebekka Rust, Helma Freitag, Franziska Sotzny, Anne Krüger, Markus Tölle, Patricia Grabowski, Carmen Scheibenbogen, Laura Kim
Journal: The Lancet Regional Health - Europe (2024)
Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin
Authors: Heehwa G Son, Dat Thinh Ha, Yun Xia, Tiancheng Li, Jasmine Blandin, Tomonori Oka, Marjan Azin, Danielle N Conrad, Can Zhou, Yuhan Zeng, Tatsuya Hasegawa, John D Strickley, Jonathan L Messerschmidt, Ranya Guennoun, Tal H Erlich, Gregory L Shoemaker, Luke H Johnson, Kenneth E Palmer, David E Fisher, Thomas D Horn, Victor A Neel, Rosalynn M Nazarian, Joongho J Joh, Shadmehr Demehri
Journal: Cancer Cell (2024)
Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host
Authors: Maria F Gonzalez-Aponte, Anna R Damato, Tatiana Simon, Nigina Aripova, Fabrizio Darby, Myung Sik Jeon, Jingqin Luo, Joshua B Rubin, Erik D Herzog
Journal: Cancer Cell (2024)

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults with a poor prognosis despite aggressive therapy. Here, we hypothesized that daily host signaling regulates tumor growth and synchronizes circadian rhythms in GBM. We find daily glucocorticoids promote or suppress GBM growth through glucocorticoid receptor (GR) signaling depending on time of day and the clock genes, Bmal1 and Cry. Blocking circadian signals, like vasoactive intestinal peptide or glucocorticoids, dramatically slows GBM growth and disease progression. Analysis of human GBM samples from The Cancer Genome Atlas (TCGA) shows that high GR expression significantly increases hazard of mortality. Finally, mouse and human GBM models have intrinsic circadian rhythms in clock gene expression in vitro and in vivo that entrain to the host through glucocorticoid signaling, regardless of tumor type or host immune status. We conclude that GBM entrains to the circadian circuit of the brain, modulating its growth through clock-controlled cues, like glucocorticoids.
Sentinel-Lymph-Node Biopsy in Early-Stage Breast Cancer — Is It Obsolete?
Authors: Monica Morrow
Journal: New England Journal of Medicine (2024)

The role of axillary surgery in the management of breast cancer has changed. Sentinel-lymph-node biopsy is used to identify nodal metastases, but recognition of the lack of therapeutic benefit of this approach, coupled with the emphasis on tumor biology for decisions about systemic therapy, has led to trials examining the elimination of sentinel-lymph-node biopsy in early-stage breast cancer. Two trials involving clinically node-negative patients with breast cancer treated without axillary surgery have now provided outcome data: Reimer et al. present in the Journal results from the INSEMA (Intergroup Sentinel Mamma) trial,1 and data from the SOUND (Sentinel Node versus Observation . . .
Progress Toward Poliomyelitis Eradication — Afghanistan, January 2023–September 2024
Authors: Colleen Mone Hardy, Mandeep Rathee, Sumangala Chaudhury, Mufti Zubair Wadood, Fazal Ather, Elizabeth Henderson, Maureen Martinez
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Since the Global Polio Eradication Initiative began in 1988, wild poliovirus (WPV) types 2 and 3 have been eradicated, and annual polio case numbers have decreased by >99.9%. WPV type 1 (WPV1) transmission remains endemic in Afghanistan and Pakistan, two countries that share a 1,600-mile (2,600-km) border. This report describes immunization and surveillance activities and progress toward polio eradication in Afghanistan during January 2023-September 2024. As of November 1, Afghanistan reported 23 WPV1 cases in 2024, with onset during January-September 30, 2024. During the 3 previous years, 12 WPV1 cases were reported, including six during 2023. In August 2021, the Taliban took control nationwide and allowed increased geographic access for poliovirus vaccination campaigns. Multiple challenges have affected polio eradication activities in Afghanistan, including mandated repatriation of approximately 1 million Afghans by Pakistan beginning in late 2023, the ongoing humanitarian crisis that limits international agency effectiveness, polio program constraints imposed by authorities, and increased restrictions on female participation in vaccination activities. House-to-house vaccination coverage reached 90%-98% of children during June-July 2024. Beginning in 2021, authorities had progressively lifted restrictions on house-to-house campaigns, but abruptly reverted to national restrictions in September 2024. Both nationwide house-to-house activities and strengthening of the routine childhood immunization program would help ensure that every vulnerable child is vaccinated and provide a pathway to polio eradication in Afghanistan.
New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, October 2024
Authors: Sarah Schillie, Jamie Loehr, Wilbur H. Chen, Charlotte A. Moser, Gabrielle Cooper, Cheryl Isenhour, Lucy A. McNamara
Journal: MMWR Morbidity and Mortality Weekly Report (2024)

Two meningococcal serogroup B vaccines are licensed for use in the United States. In August 2024, the Food and Drug Administration (FDA) changed the label for the meningococcal serogroup B MenB-4C vaccine (Bexsero) from a 2-dose schedule (intervals of 0 and ≥1 month) to a 2-dose schedule (0 and 6 months) and added a 3-dose schedule (0, 1-2, and 6 months), based on new immunogenicity data. On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) voted to update its recommendations for the MenB-4C dosing interval and schedule to align with the new FDA label. ACIP recommends extending the interval for the 2-dose series of MenB-4C from 0 and ≥1 month to 0 and 6 months for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making and has added a recommendation for a 3-dose series with doses administered at 0, 1-2, and 6 months for persons aged ≥10 years at increased risk. The updated ACIP recommendations for MenB-4C align with existing ACIP recommendations for the other FDA-licensed meningococcal serogroup B vaccine, MenB-FHbp (Trumenba).
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
Authors: Toralf Reimer, Angrit Stachs, Kristina Veselinovic, Thorsten Kühn, Jörg Heil, Silke Polata, Frederik Marmé, Thomas Müller, Guido Hildebrandt, David Krug, Beyhan Ataseven, Roland Reitsamer, Sylvia Ruth, Carsten Denkert, Inga Bekes, Dirk-Michael Zahm, Marc Thill, Michael Golatta, Johannes Holtschmidt, Michael Knauer, Valentina Nekljudova, Sibylle Loibl, Bernd Gerber
Journal: New England Journal of Medicine (2024)

BackgroundWhether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear.MethodsIn this prospective, randomized, noninferiority trial, we investigated the omission of axillary surgery as compared with sentinel-lymph-node biopsy in patients with clinically node-negative invasive breast cancer staged as T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo breast-conserving surgery. We report here the per-protocol analysis of invasive disease–free survival (the primary efficacy outcome). To show the noninferiority of the omission of axillary surgery, the 5-year invasive disease–free survival rate had to be at least 85%, and the upper limit of the confidence interval for the hazard ratio for invasive disease or death had to be below 1.271.ResultsA total of 5502 eligible patients (90% with clinical T1 cancer and 79% with pathological T1 cancer) underwent randomization in a 1:4 ratio. The per-protocol population included 4858 patients; 962 were assigned to undergo treatment without axillary surgery (the surgery-omission group), and 3896 to undergo sentinel-lymph-node biopsy (the surgery group). The median follow-up was 73.6 months. The estimated 5-year invasive disease–free survival rate was 91.9% (95% confidence interval [CI], 89.9 to 93.5) among patients in the surgery-omission group and 91.7% (95% CI, 90.8 to 92.6) among patients in the surgery group, with a hazard ratio of 0.91 (95% CI, 0.73 to 1.14), which was below the prespecified noninferiority margin. The analysis of the first primary-outcome events (occurrence or recurrence of invasive disease or death from any cause), which occurred in a total of 525 patients (10.8%), showed apparent differences between the surgery-omission group and the surgery group in the incidence of axillary recurrence (1.0% vs. 0.3%) and death (1.4% vs. 2.4%). The safety analysis indicates that patients in the surgery-omission group had a lower incidence of lymphedema, greater arm mobility, and less pain with movement of the arm or shoulder than patients who underwent sentinel-lymph-node biopsy.ConclusionsIn this trial involving patients with clinically node-negative, T1 or T2 invasive breast cancer (90% with clinical T1 cancer and 79% with pathological T1 cancer), omission of surgical axillary staging was noninferior to sentinel-lymph-node biopsy after a median follow-up of 6 years. (Funded by the German Cancer Aid; INSEMA ClinicalTrials.gov number, NCT02466737.)
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
Authors: Zhen Yang, Xinpeng Liu, Jun Zhu, Yangyang Chai, Boyi Cong, Bo Li, Wanfeng Gao, Ye Hu, Mingyue Wen, Yanfang Liu, Li Fu, Xuetao Cao
Journal: Cancer Cell (2024)
Predisposition footprints in the somatic genome of Wilms tumours
Authors: Taryn D. Treger, Jenny Wegert, Anna Wenger, Tim H. H. Coorens, Reem Al-Saadi, Paul G. Kemps, Jonathan Kennedy, Conor Parks, Nathaniel D. Anderson, Angus Hodder, Aleksandra Letunovska, Hyunchul Jung, Toochi Ogbonnah, Mi K. Trinh, Henry Lee-Six, Guillaume Morcrette, Marry M. van den Heuvel-Eibrink, Jarno Drost, Ruben van Boxtel, Eline J.M. Bertrums, Bianca F. Goemans, Evangelia Antoniou, Dirk Reinhardt, Heike Streitenberger, Barbara Ziegler, Jack Bartram, J. Ciaran Hutchinson, Gordan M. Vujanic, Christian Vokuhl, Tanzina Chowdhury, Rhoikos Furtwängler, Norbert Graf, Kathy Pritchard-Jones, Manfred Gessler, Sam Behjati
Journal: Cancer Discovery (2024)

Abstract Approximately 10% of children with cancer harbor a mutation in a predisposition gene. In children with the kidney cancer Wilms tumor, the prevalence is as high as 30%. Certain predispositions are associated with defined histological and clinical features, suggesting differences in tumorigenesis. To investigate this, we assembled a cohort of 137 children with Wilms tumor, of whom 71 had a pathogenic germline or mosaic variant. We examined 237 neoplasms (including two secondary leukemias), utilizing whole-genome sequencing, RNA sequencing, and genome-wide methylation, validating our findings in an independent cohort. Tumor development differed in children harboring a predisposition, depending on the variant gene and its developmental timing. Differences pervaded the repertoire of driver events, including high-risk mutations, the clonal architecture of normal kidneys, and the relatedness of neoplasms from the same individual. Our findings indicate that predisposition may preordain Wilms tumorigenesis, suggesting a variant-specific approach to managing children merits consideration. Significance: Tumors that arise in children with a cancer predisposition may develop through the same mutational pathways as sporadic tumors. We examined this question in the childhood kidney cancer, Wilms tumor. We found that certain predispositions dictate the genetic development of tumors, with clinical implications for these children. See related commentary by Brzezinski and Malkin, p. 258
Autonomous medical evaluation for guideline adherence of large language models
Authors: Dennis Fast, Lisa C. Adams, Felix Busch, Conor Fallon, Marc Huppertz, Robert Siepmann, Philipp Prucker, Nadine Bayerl, Daniel Truhn, Marcus Makowski, Alexander Löser, Keno K. Bressem
Journal: npj Digital Medicine (2024)

Abstract Autonomous Medical Evaluation for Guideline Adherence (AMEGA) is a comprehensive benchmark designed to evaluate large language models’ adherence to medical guidelines across 20 diagnostic scenarios spanning 13 specialties. It includes an evaluation framework and methodology to assess models’ capabilities in medical reasoning, differential diagnosis, treatment planning, and guideline adherence, using open-ended questions that mirror real-world clinical interactions. It includes 135 questions and 1337 weighted scoring elements designed to assess comprehensive medical knowledge. In tests of 17 LLMs, GPT-4 scored highest with 41.9/50, followed closely by Llama-3 70B and WizardLM-2-8x22B. For comparison, a recent medical graduate scored 25.8/50. The benchmark introduces novel content to avoid the issue of LLMs memorizing existing medical data. AMEGA’s publicly available code supports further research in AI-assisted clinical decision-making, aiming to enhance patient care by aiding clinicians in diagnosis and treatment under time constraints.
Is It Time to Abandon Surgery for Low-Risk DCIS?
Authors: Monica Morrow, Andrea V. Barrio
Journal: JAMA (2024)

E. Shelley Hwang, MD, MPH; Terry Hyslop, PhD; Thomas Lynch, PhD; Marc D. Ryser, PhD; Anna Weiss, MD; Anna Wolf, BA; Kelsey Norris, MPH; Meredith Witten, MD; Lars Grimm, MD; Stuart Schnitt, MD; Sunil Badve, MD; Rachel Factor, MD; Elizabeth Frank, MA; Deborah Collyar, BSc; Desiree Basila, MSc; Donna Pinto, BA; Mark A. Watson, MD, PhD; Robert West, MD, PhD; Louise Davies, MD, MS; Jenny L. Donovan, PhD; Ayako Shimada, MS; Yutong Li, MS; Yan Li, PhD; Antonia V. Bennett, PhD; Shoshana Rosenberg, ScD; Jeffrey Marks, PhD; Eric Winer, MD; Marc Boisvert, MD; Armando Giuliano, MD; Kelsey E. Larson, MD; Kathleen Yost, MD; Priscilla F. McAuliffe, MD; Amy Krie, MD; Nina Tamirisa, MD; Lisa A. Carey, MD; Alastair M. Thompson, MBChB, MD; Ann H. Partridge, MD, MPH; COMET Study Investigators; Vinay Gudena; Akiko Chiba; Jessica Bensenhaver; Eleni Andreopoulou; Elizabeth Mittendorf; Cindy Matsen; Rubie Jackson; Deba Sarma; Elie Dib; Heather Neuman; Tina Yen; Doreen Agnese; Rachelle Leong; Patricia Cronin; Ingrid Lizarraga; Joseph Guenther; Kristalyn Gallagher; Reema Batra; Ann Leitch; Timothy Moore; Kimberly Strickland; Moira Christoudias; Marissa Howard-McNatt; Anna Higham; Anasuya Gunturi; John Schallenkamp; Karng Log; Samantha Seaward; Heather Wright; Amy Rivere; Eric Feliberti; Lisa Lai; Jessica Cintolo-Gonzalez; Kandace McGuire; Ki Chung; Anjali Thawani; Emily Marcinkowski; Jennifer Marti; Nathalie Johnson; Sandhya Pruthi; April Phantana-Angkool; Jessica Maxwell; Sangeetha Prabhakaran; Douglas Weckstein; Mahvish Muzaffar; Sarah Sinclair; Christopher McGreevy; Steven Madden; Laura Peterson; Dan Sotirescu; Hannah Hazard; Thomas Lad; Sarah McLaughlin; Sheldon Feldman; Matthias Weiss; Suliat Nurudeen; M. Firdos Ziauddin; Anthony Jaslowski; Ivy Abraham; Faith Goldman; Nicholas DiBella; Mehra Golshan; Tuoc Dao; Howard Gross; Yolanda Tammaro; Mindy Bowie; Katharine Yao; Theodore Kim; Rebecca Aft; Alyssa Throckmorton; Jose Eugenio Najera; Lisa Yee; Jennifer Christman; Shylendra Sreenivasappa; Huong Le-Petross; Rachel Factor; Elissa Ozanne; Rinaa Punglia; Jennifer Gierisch; Lola Fayanju; Celia Kaplan; Laura Colletti; Wendy Stewart; Mary Lou Smith; Joanne Elmore; Lynn Bowlby; Constance Lehman; Stuart Schnitt; Henry Keurer; Deanna Attai; Patricia Ganz; Craig Earle; Karla Kerlikowske; Ruth Etzioni; Rosemarie Hakim; Jennifer Malin; Carol Palackdharry; David Webster; Richard L Schilsky; Robert Smith; Coralia Calomeni ; Jessica Wernberg; Ellis Levine; Gary Unzeitig; Kenneth Manning; Chiara Battelli; William Dooley; Trupti Hattiangadi; Ann Mauer; Angela Mislowsky; Jean Bao; Anne Blaes; Theresa Graves; Robert Behrens; Kerry Pulver; Walid El Ayass; Seth Miller
Intracellular endothelial cell metabolism in vascular function and dysfunction
Authors: Kathryn M Citrin, Balkrishna Chaube, Carlos Fernández-Hernando, Yajaira Suárez
Journal: Trends in Endocrinology and Metabolism (2024)

Endothelial cells (ECs) form the inner lining of blood vessels that is crucial for vascular function and homeostasis. They regulate vascular tone, oxidative stress, and permeability. Dysfunction leads to increased permeability, leukocyte adhesion, and thrombosis. ECs undergo metabolic changes in conditions such as wound healing, cancer, atherosclerosis, and diabetes, and can influence disease progression. We discuss recent research that has revealed diverse intracellular metabolic pathways in ECs that are tailored to their functional needs, including lipid handling, glycolysis, and fatty acid oxidation (FAO). Understanding EC metabolic signatures in health and disease will be crucial not only for basic biology but can also be exploited when designing new therapies to target EC-related functions in different vascular diseases.
A small TAT-TrkB peptide prevents BDNF receptor cleavage and restores synaptic physiology in Alzheimer’s disease
Authors: João Fonseca-Gomes, Tiago Costa-Coelho, Mafalda Ferreira-Manso, Sara Inteiro-Oliveira, Sandra H. Vaz, Nuno Alemãn-Serrano, Henrique Atalaia-Barbacena, Leonor Ribeiro-Rodrigues, Rita M. Ramalho, Rui Pinto, Hugo Vicente Miranda, Sara R. Tanqueiro, Carolina de Almeida-Borlido, Maria João Ramalho, Catarina Miranda-Lourenço, Rita F. Belo, Catarina B. Ferreira, Vera Neves, Diogo M. Rombo, Ricardo Viais, Juzoh Umemori, Ivo C. Martins, André Jerónimo-Santos, António Caetano, Nuno Manso, Petra Mäkinen, Mikael Marttinen, Mari Takalo, Michael Bremang, Ian Pike, Annakaisa Haapasalo, Joana A. Loureiro, Maria Carmo Pereira, Nuno C. Santos, Tiago F. Outeiro, Miguel A.R.B. Castanho, Adelaide Fernandes, Mikko Hiltunen, Carlos B. Duarte, Eero Castrén, Alexandre de Mendonça, Ana M. Sebastião, Tiago M. Rodrigues, Maria José Diógenes
Journal: Molecular Therapy (2024)
Critical role of TPRN rings in the stereocilia for hearing
Authors: Jieyu Qi, Fangzhi Tan, Liyan Zhang, Yinyi Zhou, Ziyu Zhang, Qiuhan Sun, Nianci Li, Yuan Fang, Xin Chen, Yunhao Wu, Guisheng Zhong, Renjie Chai
Journal: Molecular Therapy (2024)
Macrophage-Derived Type I IFN, Renal Tubular Epithelial Cell Polyploidization, and AKI-to-CKD Transition
Authors: Yaqin Wang, Qigang Lan, Fugang Li, Jiachuan Xiong, Hailun Xie, Shuiqin Gong, Mengying Yao, Liangjing Lv, Shaozong Qin, Wang Xin, Aihong Zhang, Siyan Zhou, Yinghui Huang, Jinghong Zhao
Journal: Journal of the American Society of Nephrology (2024)

Acute kidney injury (AKI) is recognized as a common risk factor for chronic kidney disease (CKD). Renal tubular epithelial cell polyploidization after AKI is closely associated with maladaptive repair, while the regulatory and molecular mechanisms remain poorly understood. Here, we set out to investigate the mechanism of tubular epithelial cell polyploidization and their role in the AKI-to-CKD transition.
Developmental and Cell Fate Analyses Support a Postnatal Origin for the Cortical Collecting System in the Mouse Kidney
Authors: Riana K. Parvez, Réka L. Csipán, Jing Liu, Ara Gevorgyan, Elisabeth A. Rutledge, Jinjin Guo, Dohkyung Kim, Andrew P. McMahon
Journal: Journal of the American Society of Nephrology (2024)

Structure and function in the mammalian kidney are organized along a radial axis highlighted by the corticomedullary organization and regional patterning of the collecting system. The arborised collecting epithelium arises through controlled growth, branching and commitment of Wnt11+ ureteric progenitor cells within cortically localized branch tips until postnatal day 3.
An RNA editing strategy rescues gene duplication in a mouse model of MECP2 duplication syndrome and nonhuman primates
Authors: Dong Yang, Xiaoqing Wu, Yinan Yao, Mengsi Duan, Xing Wang, Guoling Li, Aiguo Guo, Meixian Wu, Yuanhua Liu, Jin Zheng, Renxia Zhang, Tong Li, Alvin Luk, Xuan Yao, Linyu Shi, Chunlong Xu, Hui Yang
Journal: Nature Neuroscience (2024)
Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4
Authors: Mylène Gerritsen, Florentien E M In 't Hout, Ruth Knops, Bas L R Mandos, Melanie Decker, Tim Ripperger, Bert A van der Reijden, Joost H A Martens, Joop H Jansen
Journal: Leukemia (2024)
Impact of surrogates for insulin resistance on mortality and life expectancy in primary care: a nationwide cross-sectional study with registry linkage (LIPIDOGRAM2015)
Authors: Yang Chen, Ziyi Zhong, Ying Gue, Maciej Banach, Garry McDowell, Dimitri P Mikhailidis, Peter P Toth, Peter E Penson, Tomasz Tomasik, Adam Windak, Marek Gierlotka, Tadeusz Osadnik, Agnieszka Kuras, Marcin Miga, Jacek Jozwiak, Gregory Y H Lip
Journal: The Lancet Regional Health - Europe (2024)